Skip to main content
Erschienen in: Archives of Gynecology and Obstetrics 6/2023

30.01.2022 | Obstetrics and Gynecology

Analysis of immunohistochemical characteristics and recurrence after complete remission with fertility preservation treatment in patients with endometrial carcinoma and endometrial atypical hyperplasia

verfasst von: Liwei Li, Zerui Xiao, Yiqin Wang, Yijiao He, Zhiqi Wang, Danhua Shen, Jianliu Wang

Erschienen in: Archives of Gynecology and Obstetrics | Ausgabe 6/2023

Einloggen, um Zugang zu erhalten

Abstract

Objective

To investigate the relationship between immunohistochemical characteristics and recurrence after complete remission (CR) with fertility preservation treatment in patients with endometrial cancer (EC) and endometrial atypical hyperplasia (AH).

Methods

The clinical data and immunohistochemical results of 53 patients with EC and 68 patients with AH admitted to Peking University People’s Hospital from January 2010 to January 2021 were retrospectively analyzed. Patients were divided into two groups according to whether recurrence after complete remission (CR): group 1: recurrence after CR; group 2: no recurrence after CR, for statistical analysis.

Results

(1) The expression rate of ER in group 1 was lower than that in group 2, (P < 0.05). The expression rate of Ki-67 in group 1 was significantly higher than that in group 2, (P < 0.01). The expression rates of PR, P16, P53, and PTEN were not significantly different between the two groups (P > 0.05); (2) combination index ER/ Ki-67 row ROC curve analysis, there was a significant difference (P < 0.01), the best cut-off value was 3.55, sensitivity 0.730, specificity 1.000, Youden index 0.730. The 3-year RFS of high rate patients was 100%, and that of low rate patients was 42.3%, P < 0.01.

Conclusions

The expression rate of Ki-67 is of great significance in predicting the recurrence of EC after fertility preservation therapy. The best cut-off value of combination index ER/ Ki-67 (3.55) was better than a single immunohistochemical marker in predicting recurrence of EC after fertility preservation treatment.
Literatur
1.
Zurück zum Zitat Zaino RJ, Kauderer J, Trimble CL et al (2006) Reproducibility of the diagnosis of atypical endometrial hyperplasia: a Gynecologic Oncology Group study. Cancer 106(4):804–811CrossRefPubMed Zaino RJ, Kauderer J, Trimble CL et al (2006) Reproducibility of the diagnosis of atypical endometrial hyperplasia: a Gynecologic Oncology Group study. Cancer 106(4):804–811CrossRefPubMed
2.
Zurück zum Zitat Corzo C, Barrientos Santillan N, Westin SN et al (2018) Updates on conservative management of endometrial cancer. J Minim Invasive Gynecol 25(2):308–313CrossRefPubMed Corzo C, Barrientos Santillan N, Westin SN et al (2018) Updates on conservative management of endometrial cancer. J Minim Invasive Gynecol 25(2):308–313CrossRefPubMed
3.
Zurück zum Zitat Koskas M, Uzan J, Luton D et al (2014) Prognostic factors of oncologic and reproductive outcomes in fertility-sparing management of endometrial atypical hyperplasia and adenocarcinoma: systematic review and meta-analysis. Fertil Steril 101(3):785–794CrossRefPubMed Koskas M, Uzan J, Luton D et al (2014) Prognostic factors of oncologic and reproductive outcomes in fertility-sparing management of endometrial atypical hyperplasia and adenocarcinoma: systematic review and meta-analysis. Fertil Steril 101(3):785–794CrossRefPubMed
4.
Zurück zum Zitat Zhou H, Cao D, Yang J et al (2017) Gonadotropin-releasing hormone agonist combined with a levonorgestrel-releasing intrauterine system or letrozole for fertility-preserving treatment of endometrial carcinoma and complex atypical hyperplasia in young women. Int J Gynecol Cancer 27(6):1178–1182CrossRefPubMed Zhou H, Cao D, Yang J et al (2017) Gonadotropin-releasing hormone agonist combined with a levonorgestrel-releasing intrauterine system or letrozole for fertility-preserving treatment of endometrial carcinoma and complex atypical hyperplasia in young women. Int J Gynecol Cancer 27(6):1178–1182CrossRefPubMed
5.
Zurück zum Zitat Pronin SM, Novikova OV, Andreeva JY et al (2015) Fertility-sparing treatment of early endometrial cancer and complex atypical hyperplasia in young women of childbearing potential. Int J Gynecol Cancer 25(6):1010–1014CrossRefPubMed Pronin SM, Novikova OV, Andreeva JY et al (2015) Fertility-sparing treatment of early endometrial cancer and complex atypical hyperplasia in young women of childbearing potential. Int J Gynecol Cancer 25(6):1010–1014CrossRefPubMed
6.
Zurück zum Zitat Baek JS, Lee WH, Kang WD et al (2016) Fertility-preserving treatment in complex atypical hyperplasia and early endometrial cancer in young women with oral progestin: is it effective? Obstet Gynecol Sci 59(1):24–31CrossRefPubMedPubMedCentral Baek JS, Lee WH, Kang WD et al (2016) Fertility-preserving treatment in complex atypical hyperplasia and early endometrial cancer in young women with oral progestin: is it effective? Obstet Gynecol Sci 59(1):24–31CrossRefPubMedPubMedCentral
7.
Zurück zum Zitat Sasada S, Yunokawa M, Takehara Y et al (2018) Baseline risk of recurrence in stage I-II endometrial carcinoma. J Gynecol Oncol 29(1):e9CrossRefPubMed Sasada S, Yunokawa M, Takehara Y et al (2018) Baseline risk of recurrence in stage I-II endometrial carcinoma. J Gynecol Oncol 29(1):e9CrossRefPubMed
8.
Zurück zum Zitat Takahashi K, Yunokawa M, Sasada S et al (2019) A novel prediction score for predicting the baseline risk of recurrence of stage I-II endometrial carcinoma. J Gynecol Oncol 30(1):e8CrossRefPubMed Takahashi K, Yunokawa M, Sasada S et al (2019) A novel prediction score for predicting the baseline risk of recurrence of stage I-II endometrial carcinoma. J Gynecol Oncol 30(1):e8CrossRefPubMed
9.
Zurück zum Zitat Gottwald L, Pluta P, Piekarski J et al (2010) Long-term survival of endometrioid endometrial cancer patients. Arch Med Sci AMS 6(6):937–944CrossRefPubMed Gottwald L, Pluta P, Piekarski J et al (2010) Long-term survival of endometrioid endometrial cancer patients. Arch Med Sci AMS 6(6):937–944CrossRefPubMed
10.
Zurück zum Zitat Bendifallah S, Ouldamer L, Lavoue V et al (2017) Patterns of recurrence and outcomes in surgically treated women with endometrial cancer according to ESMO-ESGO-ESTRO Consensus Conference risk groups: results from the FRANCOGYN study group. Gynecol Oncol 144(1):107–112CrossRefPubMed Bendifallah S, Ouldamer L, Lavoue V et al (2017) Patterns of recurrence and outcomes in surgically treated women with endometrial cancer according to ESMO-ESGO-ESTRO Consensus Conference risk groups: results from the FRANCOGYN study group. Gynecol Oncol 144(1):107–112CrossRefPubMed
11.
Zurück zum Zitat Chen X, Luo X (2019) Fertility-preserving treatment for early stage endometrial cancer. Chin J Pract Gynecol Obstet 35(6):618–623 Chen X, Luo X (2019) Fertility-preserving treatment for early stage endometrial cancer. Chin J Pract Gynecol Obstet 35(6):618–623
12.
Zurück zum Zitat Jeon YT, Park IA, Kim YB et al (2006) Steroid receptor expressions in endometrial cancer: clinical significance and epidemiological implication. Cancer Lett 239(2):198–204CrossRefPubMed Jeon YT, Park IA, Kim YB et al (2006) Steroid receptor expressions in endometrial cancer: clinical significance and epidemiological implication. Cancer Lett 239(2):198–204CrossRefPubMed
13.
Zurück zum Zitat Gülseren V, Kocaer M, Özdemir İA et al (2020) Do estrogen, progesterone, P53, and Ki67 receptor ratios determined from curettage materials in endometrioid-type endometrial carcinoma predict lymph node metastasis? Curr Probl Cancer 44(1):100498CrossRefPubMed Gülseren V, Kocaer M, Özdemir İA et al (2020) Do estrogen, progesterone, P53, and Ki67 receptor ratios determined from curettage materials in endometrioid-type endometrial carcinoma predict lymph node metastasis? Curr Probl Cancer 44(1):100498CrossRefPubMed
14.
Zurück zum Zitat Temraz S, Shamseddine A, Mukherji D et al (2019) Ki67 and P53 in relation to disease progression in metastatic pancreatic cancer: a single institution analysis. Pathol Oncol Res POR 25(3):1059–1066CrossRefPubMed Temraz S, Shamseddine A, Mukherji D et al (2019) Ki67 and P53 in relation to disease progression in metastatic pancreatic cancer: a single institution analysis. Pathol Oncol Res POR 25(3):1059–1066CrossRefPubMed
15.
Zurück zum Zitat Li J, Liu ZY, Yu HB et al (2020) Clinicopathological significance of Ki67 expression in colorectal cancer: a protocol of systematic review and meta-analysis. Medicine 99(20):e20136CrossRefPubMedPubMedCentral Li J, Liu ZY, Yu HB et al (2020) Clinicopathological significance of Ki67 expression in colorectal cancer: a protocol of systematic review and meta-analysis. Medicine 99(20):e20136CrossRefPubMedPubMedCentral
16.
Zurück zum Zitat Jacobsen F, Kohsar J, Gebauer F et al (2020) Loss of p16 and high Ki67 labeling index is associated with poor outcome in esophageal carcinoma. Oncotarget 11(12):1007–1016CrossRefPubMedPubMedCentral Jacobsen F, Kohsar J, Gebauer F et al (2020) Loss of p16 and high Ki67 labeling index is associated with poor outcome in esophageal carcinoma. Oncotarget 11(12):1007–1016CrossRefPubMedPubMedCentral
17.
Zurück zum Zitat Gao X, Zhao L, Shen D et al (2014) Study of molecular markers in patients with endometrial carcinoma and its prognosis on the effectiveness. Chin J Clin Obstet Gynecol 15(6):519–522 Gao X, Zhao L, Shen D et al (2014) Study of molecular markers in patients with endometrial carcinoma and its prognosis on the effectiveness. Chin J Clin Obstet Gynecol 15(6):519–522
18.
Zurück zum Zitat Feng M, Hong Bu, Wang W et al (2019) Progress in molecular classification of endometrial cancer and its clinical significance. Chin J Pathol 48(12):997–1000 Feng M, Hong Bu, Wang W et al (2019) Progress in molecular classification of endometrial cancer and its clinical significance. Chin J Pathol 48(12):997–1000
19.
Zurück zum Zitat Jiang P, Jia M, Hu J et al (2020) Prognostic value of Ki67 in patients with stage 1–2 endometrial cancer: validation of the cut-off value of Ki67 as a predictive factor. OncoTargets Ther 13:10841–10850CrossRef Jiang P, Jia M, Hu J et al (2020) Prognostic value of Ki67 in patients with stage 1–2 endometrial cancer: validation of the cut-off value of Ki67 as a predictive factor. OncoTargets Ther 13:10841–10850CrossRef
20.
Zurück zum Zitat Jia M, Jiang P, Huang Z et al (2020) The combined ratio of estrogen, progesterone, Ki-67, and P53 to predict the recurrence of endometrial cancer. J Surg Oncol 122(8):1808–1814CrossRefPubMed Jia M, Jiang P, Huang Z et al (2020) The combined ratio of estrogen, progesterone, Ki-67, and P53 to predict the recurrence of endometrial cancer. J Surg Oncol 122(8):1808–1814CrossRefPubMed
Metadaten
Titel
Analysis of immunohistochemical characteristics and recurrence after complete remission with fertility preservation treatment in patients with endometrial carcinoma and endometrial atypical hyperplasia
verfasst von
Liwei Li
Zerui Xiao
Yiqin Wang
Yijiao He
Zhiqi Wang
Danhua Shen
Jianliu Wang
Publikationsdatum
30.01.2022
Verlag
Springer Berlin Heidelberg
Erschienen in
Archives of Gynecology and Obstetrics / Ausgabe 6/2023
Print ISSN: 0932-0067
Elektronische ISSN: 1432-0711
DOI
https://doi.org/10.1007/s00404-022-06398-3

Weitere Artikel der Ausgabe 6/2023

Archives of Gynecology and Obstetrics 6/2023 Zur Ausgabe

Blutdrucksenkung könnte Uterusmyome verhindern

Frauen mit unbehandelter oder neu auftretender Hypertonie haben ein deutlich erhöhtes Risiko für Uterusmyome. Eine Therapie mit Antihypertensiva geht hingegen mit einer verringerten Inzidenz der gutartigen Tumoren einher.

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

17.05.2024 Klinik aktuell Nachrichten

Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.

Antikörper-Wirkstoff-Konjugat hält solide Tumoren in Schach

16.05.2024 Zielgerichtete Therapie Nachrichten

Trastuzumab deruxtecan scheint auch jenseits von Lungenkrebs gut gegen solide Tumoren mit HER2-Mutationen zu wirken. Dafür sprechen die Daten einer offenen Pan-Tumor-Studie.

Mammakarzinom: Senken Statine das krebsbedingte Sterberisiko?

15.05.2024 Mammakarzinom Nachrichten

Frauen mit lokalem oder metastasiertem Brustkrebs, die Statine einnehmen, haben eine niedrigere krebsspezifische Mortalität als Patientinnen, die dies nicht tun, legen neue Daten aus den USA nahe.

Update Gynäkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.